Skip to main
KZR
KZR logo

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences has recently experienced the lifting of the partial clinical hold in its autoimmune hepatitis (AIH) treatment, which enhances investor confidence in its risk–benefit profile. Additionally, the potential full removal of the clinical hold for lupus nephritis (LN) could further bolster investor sentiment and support future clinical uptake, should it be approved. These developments notably improve the commercial outlook for Zetomipzomib and suggest a favorable trajectory for the company's pipeline and overall financial performance.

Bears say

Kezar Life Sciences Inc. faces challenges due to its reliance on a limited pipeline of product candidates, which raises concerns about the potential for future revenue generation in the competitive biotechnology sector. The company's clinical-stage status indicates that it has not yet commercialized any products, leading to ongoing financial losses and uncertainty surrounding its ability to secure substantial funding for continued research and development. Additionally, the lack of diversified treatments may heighten risks for investors, particularly if current trials do not yield favorable results or if there are setbacks in advancing its therapeutics to market.

KZR has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 2 analysts, KZR has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.